Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entropy NeurodynamicsTYPTF -37.73% Operating Cash Flow per Share is $0.00 as of Jun. 2026. The stock has 6 warning signs investors should review. Among 1,128 Biotechnology companies, Entropy Neurodynamics ranks better than 91.22% on this metric.
Entropy Neurodynamics's operating cash flow per share for the
six
months ended in Jun. 2026 was $0.00.
Entropy Neurodynamics's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Entropy Neurodynamics was -166.70% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 64.40% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 38.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Entropy Neurodynamics's Operating Cash Flow per Share or its related term are showing as below:
TYPTF'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -12.2 Med: 32.3 Max: 64.4
Current: 64.4
During the past 11 years, Entropy Neurodynamics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 64.40% per year. The lowest was -12.20% per year. And the median was 32.30% per year.
TYPTF's 3-Year OCF Growth Rate is ranked better than 91.22% of 1128
companies
in the Biotechnology industry
Industry Median: 16.95
vs TYPTF: 64.40
Entropy Neurodynamics Operating Cash Flow per Share Related Terms
Entropy Neurodynamics Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Entropy Neurodynamics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entropy Neurodynamics Operating Cash Flow per Share Chart
TYPTF vs VRTX, REGN, MRNA: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Entropy Neurodynamics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entropy Neurodynamics Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Entropy Neurodynamics's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $0.00 mean?
Entropy Neurodynamics (TYPTF) has a Operating Cash Flow per Share of $0.00 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Entropy Neurodynamics and its competitors. According to the industry distribution chart, Entropy Neurodynamics ranks #99 out of 1128 companies in the Biotechnology industry, placing it in the top 8.8%.
Is Entropy Neurodynamics' Operating Cash Flow per Share too high?
Entropy Neurodynamics' current Operating Cash Flow per Share is $0.00. Based on the distribution chart, Entropy Neurodynamics ranks #99 out of 1128 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Entropy Neurodynamics' Operating Cash Flow per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #99 out of 1128 companies for Operating Cash Flow per Share. This places Entropy Neurodynamics in the top 9% of its industry — outperforming the majority of peers. The industry median Operating Cash Flow per Share is 16.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 16.95, based on 1,128 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Entropy Neurodynamics and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 16.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entropy Neurodynamics's current Operating Cash Flow per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 70% above its estimated fair value. The current Operating Cash Flow per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current Operating Cash Flow per Share is $0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYPTF has been successfully added to your 
